Case Report: Immune-mediated Meibomian Gland Dysfunction Following Pembrolizumab Therapy for Advanced Urothelial Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 24

PMID 36276085

Authors

Charles B Nguyen

Christopher T Su

Meredith Morgan

Ajjai S Alva

Affiliations

Soon will be listed here.

Abstract

Ocular immune-related adverse events are a relatively rare complication of immune checkpoint inhibitors. Common ocular toxicities range from dry eyes to inflammatory uveitis and ocular myasthenia gravis. Here, we present the case of a 55-year-old woman with recurrent urothelial carcinoma of the ureter after initially being managed with neoadjuvant cisplatin-based chemotherapy and surgical resection. She was treated with pembrolizumab which was complicated by immune-mediated pneumonitis after the eighth cycle, which was managed with a prolonged steroid course. The patient also developed red eyes along with recurrent styes. Eye examination revealed decreased tear breakup time, expression of thick and turbid meibum, and meibomian gland atrophy on infrared meibography. The patient was diagnosed with suspected immune-mediated meibomian gland dysfunction (MGD) as a result of pembrolizumab, a previously unreported complication of immunotherapy. The goal of MGD therapy is to stabilize the tear film and minimize evaporation with lipid-based lubricants and other conservative treatments.

References

Hassan A, Balal S, Ahmad S . Meibomian gland dysfunction, dropout and distress: emerging therapies. Eye (Lond). 2020; 34(9):1494-1496. PMC: 7609286. DOI: 10.1038/s41433-020-0865-5. View

Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, OBrien T . The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011; 52(4):2050-64. PMC: 3072163. DOI: 10.1167/iovs.10-6997g. View

Srivastava A, Al-Zubidi N, Appelbaum E, Gombos D, Nader M, Gidley P . Immune-Related Oral, Otologic, and Ocular Adverse Events. Adv Exp Med Biol. 2020; 1244:295-307. DOI: 10.1007/978-3-030-41008-7_17. View

Tonini G, Vincenzi B, Santini D, Olzi D, Lambiase A, Bonini S . Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst. 2005; 97(8):606-7. DOI: 10.1093/jnci/dji104. View

Sullivan D, Dana R, Sullivan R, Krenzer K, Sahin A, Arica B . Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome. Ophthalmic Res. 2018; 59(4):193-205. DOI: 10.1159/000487487. View

Liu Y, Wang Y, Jin X, Zhang N, Shi Y, Zhu R . Observation of Conjunctiva-Associated Lymphoid Tissue With In Vivo Confocal Microscopy in Healthy Patients and Patients With Meibomian Gland Dysfunction. Cornea. 2021; 41(9):1129-1136. PMC: 9365257. DOI: 10.1097/ICO.0000000000002910. View

Machalinska A, Zakrzewska A, Markowska A, Safranow K, Wiszniewska B, Parafiniuk M . Morphological and Functional Evaluation of Meibomian Gland Dysfunction in Rosacea Patients. Curr Eye Res. 2015; 41(8):1029-1034. DOI: 10.3109/02713683.2015.1088953. View

Chhadva P, Goldhardt R, Galor A . Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease. Ophthalmology. 2017; 124(11S):S20-S26. PMC: 5685175. DOI: 10.1016/j.ophtha.2017.05.031. View

Tomlinson A, Bron A, Korb D, Amano S, Paugh J, Pearce E . The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011; 52(4):2006-49. PMC: 3072162. DOI: 10.1167/iovs.10-6997f. View

10.

Brouwer N, Haanen J, Jager M . Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. Ocul Oncol Pathol. 2017; 3(3):188-192. PMC: 5649334. DOI: 10.1159/000455150. View

11.

Gupta P, Periman L, Lain E, Donnenfeld E, Hovanesian J, Kim T . Meibomian Gland Dysfunction: A Dermatological Perspective on Pathogenesis and Treatment Outlook. Clin Ophthalmol. 2021; 15:4399-4404. PMC: 8590836. DOI: 10.2147/OPTH.S327407. View

12.

Grob S, Jakobiec F, Rashid A, Yoon M . Chalazia associated with bortezomib therapy for multiple myeloma. Ophthalmology. 2014; 121(9):1845-7.e3. DOI: 10.1016/j.ophtha.2014.04.021. View

13.

Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M . Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017; 17(4):387-394. DOI: 10.1080/14737140.2017.1296765. View

14.

Dalvin L, Shields C, Orloff M, Sato T, Shields J . CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018; 38(6):1063-1078. DOI: 10.1097/IAE.0000000000002181. View

15.

Liu R, Rong B, Tu P, Tang Y, Song W, Toyos R . Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction. Am J Ophthalmol. 2017; 183:81-90. DOI: 10.1016/j.ajo.2017.08.021. View

16.

Fang T, Maberley D, Etminan M . Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019; 31(3):319-322. PMC: 6742617. DOI: 10.1016/j.joco.2019.05.002. View

17.

Nichols K, Foulks G, Bron A, Glasgow B, Dogru M, Tsubota K . The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011; 52(4):1922-9. PMC: 3072157. DOI: 10.1167/iovs.10-6997a. View

18.

Bomze D, Meirson T, Ali O, Goldman A, Flatz L, Habot-Wilner Z . Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul Immunol Inflamm. 2020; 30(1):191-197. DOI: 10.1080/09273948.2020.1773867. View

19.

Chen X, Badian R, Hynne H, Amdal C, Herlofson B, Aass Utheim O . Alterations in meibomian glands in patients treated with intensity-modulated radiotherapy for head and neck cancer. Sci Rep. 2021; 11(1):22419. PMC: 8599465. DOI: 10.1038/s41598-021-01844-9. View

20.

Liu X, Wang Z, Zhao C, Wang H, Guo X, Zhou J . Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer. 2020; 11(3):810-818. PMC: 7049480. DOI: 10.1111/1759-7714.13327. View